iDose TR Administration in an Office-Based Surgery Setting
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGlaukos Corporation
About this trial
Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)
Disqualifiers
Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye
Active ocular infection or inflammation
History of hypersensitivity to travoprost or implant components
Recent ocular surgery
Trial population
Adults 18 years of age or older with open-angle glaucoma or ocular hypertension
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
iDose TR (travoprost intracameral implant) 75 µg
Combination productTravoprost-releasing implant preloaded in a sterile, single-use inserter.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: iDose TR1 intervention
Trial outcomes
Primary outcomes
1
Successful administration of iDose TR in an office-based surgical setting.
Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.
Time frame
3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov